Role of Ubiquitination in IGF-1 Receptor Signaling and Degradation

Background The insulin-like growth factor 1 receptor (IGF-1R) plays numerous crucial roles in cancer biology. The majority of knowledge on IGF-1R signaling is concerned with its role in the activation of the canonical phosphatidyl inositol-3 kinase (PI3K)/Akt and MAPK/ERK pathways. However, the role of IGF-1R ubiquitination in modulating IGF-1R function is an area of current research. In light of this we sought to determine the relationship between IGF-1R phosphorylation, ubiquitination, and modulation of growth signals. Methodology Wild type and mutant constructs of IGF-1R were transfected into IGF-1R null fibroblasts. IGF-1R autophosphorylation and ubiquitination were determined by immunoprecipitation and western blotting. IGF-1R degradation and stability was determined by cyclohexamide-chase assay in combination with lysosome and proteasome inhibitors. Principal Findings IGF-1R autophosphorylation was found to be an absolute requirement for receptor ubiquitination. Deletion of C-terminal domain had minimal effect on IGF-1 induced receptor autophosphorylation, however, ubiquitination and ERK activation were completely abolished. Cells expressing kinase impaired IGF-1R, exhibited both receptor ubiquitination and ERK phosphorylation, however failed to activate Akt. While IGF-1R mutants with impaired PI3K/Akt signaling were degraded mainly by the proteasomes, the C-terminal truncated one was exclusively degraded through the lysosomal pathway. Conclusions Our data suggest important roles of ubiquitination in mediating IGF-1R signaling and degradation. Ubiquitination of IGF-1R requires receptor tyrosine kinase activity, but is not involved in Akt activation. In addition we show that the C-terminal domain of IGF-1R is a necessary requisite for ubiquitination and ERK phosphorylation as well as for proteasomal degradation of the receptor.

[1]  Robert J. Lefkowitz,et al.  β-Arrestin and Mdm2 Mediate IGF-1 Receptor-stimulated ERK Activation and Cell Cycle Progression* , 2007, Journal of Biological Chemistry.

[2]  S. Hajduk,et al.  Serum Resistance-Associated Protein Blocks Lysosomal Targeting of Trypanosome Lytic Factor in Trypanosoma brucei , 2006, Eukaryotic Cell.

[3]  O. Larsson,et al.  β-Arrestin Is Crucial for Ubiquitination and Down-regulation of the Insulin-like Growth Factor-1 Receptor by Acting as Adaptor for the MDM2 E3 Ligase* , 2005, Journal of Biological Chemistry.

[4]  O. Larsson,et al.  Role of insulin-like growth factor 1 receptor signalling in cancer , 2005, British Journal of Cancer.

[5]  P. Transidico,et al.  Clathrin-independent endocytosis of ubiquitinated cargos. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[6]  O. Larsson,et al.  The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway , 2004, Oncogene.

[7]  D. Bredesen,et al.  Paraptosis: mediation by MAP kinases and inhibition by AIP-1/Alix , 2004, Cell Death and Differentiation.

[8]  O. Larsson,et al.  Cyclolignans as Inhibitors of the Insulin-Like Growth Factor-1 Receptor and Malignant Cell Growth , 2004, Cancer Research.

[9]  David S. Park,et al.  Caveolin-1 null (-/-) mice show dramatic reductions in life span. , 2003, Biochemistry.

[10]  E. J. V. van Zoelen,et al.  Ligand-induced Lysosomal Epidermal Growth Factor Receptor (EGFR) Degradation Is Preceded by Proteasome-dependent EGFR De-ubiquitination* , 2003, Journal of Biological Chemistry.

[11]  O. Larsson,et al.  Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[12]  A. Vecchione,et al.  The Grb10/Nedd4 Complex Regulates Ligand-Induced Ubiquitination and Stability of the Insulin-Like Growth Factor I Receptor , 2003, Molecular and Cellular Biology.

[13]  Pier Paolo Di Fiore,et al.  Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation , 2003, Nature Cell Biology.

[14]  C. Thompson,et al.  Akt Activation Promotes Degradation of Tuberin and FOXO3a via the Proteasome* , 2003, The Journal of Biological Chemistry.

[15]  Hiroshi Watanabe,et al.  Redundancy of Radioresistant Signaling Pathways Originating from Insulin-like Growth Factor I Receptor* , 2002, The Journal of Biological Chemistry.

[16]  P. Kloetzel,et al.  PI31 is a modulator of proteasome formation and antigen processing , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[17]  D. Woods,et al.  Phosphorylation of HDM2 by Akt , 2002, Oncogene.

[18]  Stevan R. Hubbard,et al.  Structure and autoregulation of the insulin-like growth factor 1 receptor kinase , 2001, Nature Structural Biology.

[19]  L. Mayo,et al.  A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[20]  A. Dautry‐Varsat,et al.  Involvement of the ubiquitin/proteasome system in sorting of the interleukin 2 receptor beta chain to late endocytic compartments. , 2001, Molecular biology of the cell.

[21]  M. Hung,et al.  Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells , 2001, Nature Cell Biology.

[22]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[23]  Peter Jackson,et al.  The lore of the RINGs: substrate recognition and catalysis by ubiquitin ligases. , 2000, Trends in cell biology.

[24]  T. Rohan,et al.  Role of the insulin-like growth factor family in cancer development and progression. , 2000, Journal of the National Cancer Institute.

[25]  G. Nilsson,et al.  Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: functional impact. , 2000, Cancer research.

[26]  R. Baserga.  The IGF-I receptor in cancer research. , 1999, Experimental cell research.

[27]  A. Bell,et al.  Negative Regulation of Epidermal Growth Factor Signaling by Selective Proteolytic Mechanisms in the Endosome Mediated by Cathepsin B* , 1999, The Journal of Biological Chemistry.

[28]  R. Gardner,et al.  A ‘distributed degron’ allows regulated entry into the ER degradation pathway , 1999, The EMBO journal.

[29]  C. Crews,et al.  Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[30]  D. Bowtell,et al.  The Cbl protooncoprotein stimulates CSF‐1 receptor multiubiquitination and endocytosis, and attenuates macrophage proliferation , 1999, The EMBO journal.

[31]  J. Rine,et al.  Sequence determinants for regulated degradation of yeast 3-hydroxy-3-methylglutaryl-CoA reductase, an integral endoplasmic reticulum membrane protein. , 1998, Molecular biology of the cell.

[32]  A. Sorkin,et al.  Endocytosis and intracellular sorting of receptor tyrosine kinases. , 1998, Frontiers in bioscience : a journal and virtual library.

[33]  G. Condorelli,et al.  Insulin-like Growth Factor-I Receptor Internalization Regulates Signaling via the Shc/Mitogen-activated Protein Kinase Pathway, but Not the Insulin Receptor Substrate-1 Pathway* , 1998, The Journal of Biological Chemistry.

[34]  B. R. Dey,et al.  14-3-3 proteins interact with the insulin-like growth factor receptor but not the insulin receptor. , 1997, The Biochemical journal.

[35]  M. Rubini,et al.  The IGF-I receptor in mitogenesis and transformation of mouse embryo cells: role of receptor number. , 1997, Experimental cell research.

[36]  E. Van Obberghen,et al.  Evidence for a Differential Interaction of SHC and the Insulin Receptor Substrate-1 (IRS-1) with the Insulin-like Growth Factor-I (IGF-I) Receptor in the Yeast Two-hybrid System (*) , 1995, The Journal of Biological Chemistry.

[37]  H. Werner,et al.  The Role of the Insulin‐like Growth Factor‐I Receptor in Cancer , 1995, Annals of the New York Academy of Sciences.

[38]  T. O’Neill,et al.  Non-SH2 Domains within Insulin Receptor Substrate-1 and SHC Mediate Their Phosphotyrosine-dependent Interaction with the NPEY Motif of the Insulin-like Growth Factor I Receptor (*) , 1995, The Journal of Biological Chemistry.

[39]  A. Ferber,et al.  Mitogenicity and transforming activity of the insulin-like growth factor-I receptor with mutations in the tyrosine kinase domain. , 1994, The Journal of biological chemistry.

[40]  D. Lauffenburger,et al.  Regulation of postendocytic trafficking of the epidermal growth factor receptor through endosomal retention. , 1994, The Journal of biological chemistry.

[41]  J. Welsh,et al.  Ligand-induced transformation by a noninternalizing epidermal growth factor receptor. , 1990, Science.

[42]  P. Tulkens,et al.  Commentary. Lysosomotropic agents. , 1974, Biochemical pharmacology.

[43]  O. Larsson,et al.  Beta-arrestin and Mdm2 mediate IGF-1 receptor-stimulated ERK activation and cell cycle progression. , 2007, The Journal of biological chemistry.

[44]  R. de Caterina,et al.  Differential Ability of Human Endothelial Cells to Internalize and Express Exogenous DNA , 2004, Cardiovascular Drugs and Therapy.

[45]  J. Wrana,et al.  Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover. , 2003, Nature cell biology.

[46]  R. Baserga.  Insulin-like growth factor I receptor signalling in prostate cancer cells. , 2000, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.